Loading AI tools
Pharmaceutical drug From Wikipedia, the free encyclopedia
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).[4]
Clinical data | |
---|---|
Trade names | Oxervate |
Other names | Recombinant human nerve growth factor; rhNGF, cenegermin-bkbj |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619001 |
License data |
|
Pregnancy category |
|
Routes of administration | Ophthalmic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C583H908N166O173S8 |
Molar mass | 13267.15 g·mol−1 |
The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.[5]
It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]
Cenegermin is indicated for the treatment of neurotrophic keratitis.[4][5]
Cenegermin is the international nonproprietary name.[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.[7]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.